Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · cited 1×
“Mutations of PTEN, a tumor suppressor, have been found in human cancers arising from uterine endometrium, breast, ovary, prostate, brain, and melanocyte (Li et al., 1997; Risinger et al., 1997; Steck et al., 1997; Obata et al., 1998).”
BackgroundSteck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,172
Self-citationKrox-20 controls myelination in the peripheral nervous system
Topilko, P., Schneider-Maunoury, S., Levi, G., Baron-Van Evercooren, A., Chennoufi, A. B. Y., Seitanidou, T., Babinet, C., & Charnay, P. (1994) · Nature · doi:10.1038/371796a0 · Cited by 794
The POZ domain: a conserved protein-protein interaction motif.
Bardwell, V. J., & Treisman, R. (1994) · Genes & Development · doi:10.1101/gad.8.14.1664 · Cited by 751
PTEN/MMAC1 mutations in endometrial cancers.
Risinger, J. I., Hayes, A. K., Berchuck, A., & Barrett, J. C. (1997) · PubMed · Cited by 506
Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies
Warner, L. E., Mancias, P., Butler, I. J., McDonald, C. M., Keppen, L., Koob, K. G., & Lupski, J. R. (1998) · Nature Genetics · doi:10.1038/ng0498-382 · Cited by 500
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
A gene encoding a protein with zinc fingers is activated during G0/G1 transition in cultured cells.
Chavrier, P., Zerial, M., Lemaire, P., Almendral, J., Bravo, R., & Charnay, P. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02780.x · Cited by 415
Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., & Nakamura, Y. (2000) · PubMed · Cited by 345
Self-citation
Cited by
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
“…exon PARK6 gene encodes the 581 amino acid protein phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) (Valente et al., 2004), a name stemming from its prior identification in a screen for proteins transcriptionally upregulated by exogenous PTEN overexpression (Unoki and Nakamura, 2001).”
BackgroundMitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.-W., Yang, L., Beal, M. F., Vogel, H., & Lu, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602493103 · Cited by 798
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
THE BIOCHEMISTRY OF PARKINSON'S DISEASE
Cookson, M. R. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 664
PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis
Bueno, M., Lai, Y.-C., Romero, Y., Brands, J., St. Croix, C. M., Kamga, C., Corey, C., Herazo-Maya, J. D., Sembrat, J., Lee, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74942 · Cited by 627
Salivary Transcriptome Diagnostics for Oral Cancer Detection
Li, Y., St. John, M. A. R., Zhou, X., Kim, Y., Sinha, U., Jordan, R. C. K., Eisele, D., Abemayor, E., Elashoff, D., Park, N.-H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1167 · Cited by 625
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 540
Protean PTEN: Form and Function
Waite, K. A., & Eng, C. (2002) · The American Journal of Human Genetics · doi:10.1086/340026 · Cited by 457
“Unoki and Nakamura have used global expression analysis to demonstrate that EGR2 and BPOZ are involved in PTEN signaling (Unoki and Nakamura 2001).”
BackgroundMitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism
Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E. M., & Casari, G. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi377 · Cited by 450
de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Beilina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, D. W., Petsko, G. A., & Cookson, M. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500617102 · Cited by 381
PINK1 protein in normal human brain and Parkinson's disease
Gandhi, S. (2006) · Brain · doi:10.1093/brain/awl114 · Cited by 342
BTB/POZ Domain Proteins Are Putative Substrate Adaptors for Cullin 3 Ubiquitin Ligases
Geyer, R., Wee, S., Anderson, S., Yates, J., & Wolf, D. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00341-1 · Cited by 338
Petit, A., Kawarai, T., Paitel, E., Sanjo, N., Maj, M., Scheid, M., Chen, F., Gu, Y., Hasegawa, H., Salehi-Rad, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505143200 · Cited by 329
PTEN hamartoma tumor syndromes
Blumenthal, G. M., & Dennis, P. A. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.162 · Cited by 327
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002455 · Cited by 316
“. PINK1 mRNA is ubiquitously expressed in human tissues, with highest expression in heart, muscle and testes”
The kinase domain of mitochondrial PINK1 faces the cytoplasm
Zhou, C., Huang, Y., Shao, Y., May, J., Prou, D., Perier, C., Dauer, W., Schon, E. A., & Przedborski, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802814105 · Cited by 315
The N‐myc downstream regulated gene (NDRG) family: diverse functions, multiple applications
Melotte, V., Qu, X., Ongenaert, M., van Criekinge, W., de Bruïne, A. P., Baldwin, H. S., & van Engeland, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-151464 · Cited by 285
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
Dodson, M. W., & Guo, M. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.04.010 · Cited by 278
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP
Haque, M. E., Thomas, K. J., D'Souza, C., Callaghan, S., Kitada, T., Slack, R. S., Fraser, P., Cookson, M. R., Tandon, A., & Park, D. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705363105 · Cited by 263
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
“PINK1 was initially identified as a kinase that was upregulated on overexpression of PTEN, a tumour-suppressor gene, suggesting that PINK1 may play a role in cell cycle regulation (43).”
BackgroundTruban, D., Hou, X., Caulfield, T. R., Fiesel, F. C., & Springer, W. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160989 · Cited by 237
“An electrochemical gradient ( m) across the inner mitochondrial membrane (IMM) is important for ATP production ∗Correspondence to: Wolfdieter Springer, PhD, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.”
BackgroundKung-Chun Chiu, D., Pui-Wah Tse, A., Law, C.-T., Ming-Jing Xu, I., Lee, D., Chen, M., Kit-Ho Lai, R., Wai-Hin Yuen, V., Wing-Sum Cheu, J., Wai-Hung Ho, D., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2155-3 · Cited by 192
Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression
Bandyopadhyay, S., Pai, S. K., Hirota, S., Hosobe, S., Takano, Y., Saito, K., Piquemal, D., Commes, T., Watabe, M., Gross, S. C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207734 · Cited by 194
“…several groups independently identified Drg-1 as a target of various stimuli, including hypoxia, androgen, homocysteine, Ni2þ , N-Myc and PTEN (Kokame et al., 1996; Lin and Chang, 1997; Zhou et al., 1998; Okuda and Kondoh, 1999; Ulrix et al., 1999; Park et al., 2000; Unoki and Nakamura, 2001).”
BackgroundThe impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease
Zuo, L., & Motherwell, M. S. (2013) · Gene · doi:10.1016/j.gene.2013.07.085 · Cited by 194
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
Kovacevic, Z., & Richardson, D. R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl146 · Cited by 193
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Mei, Y., Zhang, Y., Yamamoto, K., Xie, W., Mak, T. W., & You, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901104106 · Cited by 172
Parkin and PINK1 functions in oxidative stress and neurodegeneration
Barodia, S. K., Creed, R. B., & Goldberg, M. S. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.004 · Cited by 167
“PINK1 was first cloned in the course of a search for genes upregulated by the tumor suppressor gene PTEN (Unoki and Nakamura 2001).”
BackgroundInfluentialPINK1 function in health and disease
Deas, E., Plun‐Favreau, H., & Wood, N. W. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900024 · Cited by 154
“PINK1 therefore appeared to be a novel candidate as a mediator of the PTEN growth-suppressive signalling pathway.”
BackgroundInfluentialTo die or grow: Parkinson's disease and cancer
WEST, A., DAWSON, V, & DAWSON, T. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.05.002 · Cited by 117
PINK1: The guard of mitochondria
Wang, N., Zhu, P., Huang, R., Wang, C., Sun, L., Lan, B., He, Y., Zhao, H., & Gao, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118247 · Cited by 107
Fragoso, M. C. B. V., Almeida, M. Q., Mazzuco, T. L., Mariani, B. M. P., Brito, L. P., Gonçalves, T. C., Alencar, G. A., Lima, L. D. O., Faria, A. M., Bourdeau, I., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0806 · Cited by 93
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
“Transition metals have been implicated in many neurological diseases such as Alzheimer’s disease (AD) [49, 274, 426], Multiple Sclerosis (MS) [242, 284] as well as PD [19, 20, 90, 92, 259, 375].”
BackgroundExpression of PINK1 mRNA in human and rodent brain and in Parkinson's disease
Blackinton, J. G., Anvret, A., Beilina, A., Olson, L., Cookson, M. R., & Galter, D. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.056 · Cited by 59
Restriction of trophic factors and nutrients induces PARKIN expression
Klinkenberg, M., Gispert, S., Dominguez-Bautista, J. A., Braun, I., Auburger, G., & Jendrach, M. (2012) · neurogenetics · doi:10.1007/s10048-011-0303-8 · Cited by 42
Salemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
“PARK6 may also have anti-proliferative functions [51,52].”
Molecular Network-Based Identification of Competing Endogenous RNAs in Thyroid Carcinoma
Lu, M., Xu, X., Xi, B., Dai, Q., Li, C., Su, L., Zhou, X., Tang, M., Yao, Y., & Yang, J. (2018) · Genes · doi:10.3390/genes9010044 · Cited by 25
“As a vital TF exhibiting higher transcriptional activity in PTC samples than in control, EGR2 functions as a tumor suppressor that is generally decreased in numerous cancer types such as ovarian [71] and gastric cancer [72].”
Background
Metadata
- Authors
- Unoki, M., & Nakamura, Y.
- Venue
- Oncogene
- Published
- 2001-07-27
- Volume
- 20
- Issue
- 33
- Pages
- 4457-4465
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1993733276
- Cited by
- 381
- References
- 29
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.